25 To 99 Amino Acid Residues In The Peptide Chain Patents (Class 514/21.3)
-
Publication number: 20120201753Abstract: Disclosed are compositions and methods useful for targeting regenerating tissue, wounds, and tumors. The compositions and methods are based on peptide sequences that selectively bind to and home to regenerating tissue, wound sites, and tumors in animals. The disclosed targeting is useful for delivering therapeutic and detectable agents to regenerating tissue, wound sites, and tumors in animals.Type: ApplicationFiled: April 19, 2012Publication date: August 9, 2012Inventors: Erkki Ruoslahti, Tero Jarvinen
-
Publication number: 20120204281Abstract: This invention features methods and compositions useful for treating and diagnosing diseases of the nervous system, retina, skin, muscle, joint, and cartilage using a Dragon family protein. Protein and nucleic acid sequences of human, murine, zebrafish, and C. elegans Dragon family members are also disclosed.Type: ApplicationFiled: February 28, 2012Publication date: August 9, 2012Inventors: Clifford J. WOOLF, Tarek A. Samad
-
Publication number: 20120202733Abstract: Peptides are provided consisting of L- and/or D-amino acids and combinations thereof, which affect myeloid cells by action on the triggering receptors expressed on myeloid cells (TREMs), including TREM-1 and TREM-2. The peptides act on the TREM/DAP-12 signaling complex. Also provided are lipid and sugar conjugated peptides comprising L- or D-amino acids. A method is provided of designing the peptides and lipid- and/or sugar-conjugated peptides comprising L- or D-amino acids. The disclosure relates to the therapy of various myeloid cell-related disease states involving the use of these peptides and compounds. The peptides and compounds are useful in the treatment and/or prevention of a disease or condition where myeloid cells are involved or recruited. The peptides of the present invention also are useful in the production of medical devices comprising peptide matrices (for example, medical implants and implantable devices).Type: ApplicationFiled: October 13, 2010Publication date: August 9, 2012Applicant: SIGNABLOK, INC.Inventor: Alexander B. Sigalov
-
Patent number: 8236759Abstract: The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefore comprising said analogues.Type: GrantFiled: June 30, 2006Date of Patent: August 7, 2012Assignee: Ipsen Pharma SASInventors: Zheng Xin Dong, Roland Cherif-Cheikh, Resurreccion Alloza Miravete, Jose-Antonio Cordero Rigol, Frederic Lacombe, Maria Dolores Tobalina Maestre
-
Publication number: 20120197059Abstract: The present invention involves the use peptides comprising ubiquitin interacting motifs (UIMs) alone or in combination with other agents to treat diseases involving neovascularization, such as cancer.Type: ApplicationFiled: January 31, 2012Publication date: August 2, 2012Inventors: YUNZHOU DONG, Hong Chen
-
Publication number: 20120196796Abstract: The present invention relates to novel compounds having a function of a peptide in the amylin family, related nucleic acids, expression constructs, host cells, and processes production of the compounds. The compounds of the invention include one or more amino acid sequence modifications. In addition, methods and compositions are disclosed to treat and prevent metabolic disorders such as obesity, diabetes, and increased cardiovascular risk.Type: ApplicationFiled: February 1, 2012Publication date: August 2, 2012Applicant: Amylin Pharmaceuticals, Inc.Inventors: Christopher J. Soares, Michael R. Hanley, Diana Yvonne Lewis, David Geoffrey Parkes, Carolyn Marie Jodka, Kathryn S. Prickett, Soumitra Ghosh, Christine Marie Mack, Qing Lin
-
Publication number: 20120196795Abstract: The invention provides a novel Exendin variant and the Exendin variant conjugate conjugating polymer thereon, the pharmaceutical composition comprising them and use of them for treating diseases such as reducing blood glucose, treating diabetes, especially Type II diabetes. The invention also provides the use of Exendin conjugate for lowering body weight.Type: ApplicationFiled: April 23, 2010Publication date: August 2, 2012Applicant: PEGBIO CO., LTD.Inventors: Michael M. Xu, Yongxiang Wang, Yinghui Zhang, Xiaosu Luo, Nian Gong, Lijie Zhang, Xiangjun Zhou
-
Patent number: 8232252Abstract: A novel P-selectin ligand glycoprotein is disclosed, comprising the amino acid sequence set forth in SEQ ID NO:2 or by the amino acid sequence set forth in SEQ ID NO:4. DNA sequences encoding the P-selectin ligand protein are also disclosed, along with vectors, host cells, and methods of making the P-selectin ligand protein. Pharmaceutical compositions containing the P-selectin ligand protein and methods of treating inflammatory disease states characterized by P-selectin- and E-selectin-mediated intercellular adhesion are also disclosed.Type: GrantFiled: July 3, 2008Date of Patent: July 31, 2012Assignee: Genetics Institute, LLCInventors: Glenn R. Larsen, Dianne S. Sako, Xiao-Jia Chang, Geertruida M. Veldman, Dale Cumming, Ravindra Kumar, Gray Shaw
-
Publication number: 20120190626Abstract: The present invention provides a peptide which functions as a mimic peptide of an amyloid ? peptide and is capable of inhibiting the fibrillogenesis of an amyloid ? peptide. The present invention relates to an 8- to 30-amino acid residue peptide comprising an amino acid sequence represented by the following formula (I): X1-Asp-X2-X3-X4-Pro-X5-X6 (SEQ ID NO: 28) (I), wherein X1 represents a branched chain amino acid, and X2, X3, X4, X5, and X6 are the same or different and each represents an ?-amino acid, and to a pharmaceutical composition and an amyloid ? fibrillogenesis inhibitor comprising the peptide.Type: ApplicationFiled: December 16, 2011Publication date: July 26, 2012Inventor: Kazuhisa SUGIMURA
-
Patent number: 8227421Abstract: Novel fluorinated synthetic analogs of hGH-RH(1-30)NH2 that inhibit the release of growth hormone from the pituitary in mammals as well as inhibit the proliferation of human cancers through a direct effect on the cancer cells, and to therapeutic compositions containing these novel peptides and their use.Type: GrantFiled: September 17, 2009Date of Patent: July 24, 2012Assignees: University of Miami, The United States of America represented by the Department of Veteran AffairsInventors: Andrew Schally, Jozsef Varga, Marta Zarandi, Ren Zhi Cai
-
Patent number: 8227419Abstract: The invention provides a method for improving airway conductance in a subject in need thereof, the method comprising administering to the subject an effective amount of one or more of tumstatin; a derivative, variant or homologue thereof, a polynucleotide encoding tumstatin or a derivative, variant or homologue thereof; or an agent capable of increasing the expression or production of tumstatin.Type: GrantFiled: February 2, 2007Date of Patent: July 24, 2012Assignee: CRC For Asthma and Airways Ltd.Inventors: Sarah Boustany, Janette Kay Burgess, Judith Lee Black, Brian Gregory George Oliver
-
Patent number: 8227412Abstract: Bioactive peptides that have a molecular weight of approximately 4.5 kDa and correspond to amino-terminal fragments of protease-activated receptor-1 (PAR-1), which are cleaved and released upon the proteolytic activation of PAR-1 by proteases including, but not limited to, thrombin in humans and animals are disclosed. Such synthetic or recombinantly expressed or endogenously produced or chimeric synthetic peptides that are active in vitro and in vivo and modulate endothelial cell functions and physiological and pathological processes are named herein as parstatin. Parstatin peptides, fragments, analogs, derivatives have the ability to inhibit endothelial cell growth, migration and differentiation, to induce endothelial cell apoptosis, to block angiogenesis and have cardioprotective effects in ischemia/reperfusion injury. Methods for treating angiogenesis-related diseases and endothelium dysfunction-related cardiovascular diseases are disclosed.Type: GrantFiled: March 25, 2008Date of Patent: July 24, 2012Inventors: Nikos E. Tsopanoglou, Michael E. Maragoudakis
-
Patent number: 8227406Abstract: The invention relates to an antimicrobial peptide comprising a first set of amino acid residues having a length of from about 2 to about 36 amino acid residues or analogues thereof linked to the amino or carboxyterminal end a second set comprising from 3 to 8 hydrophobic amino acid residue or analogue thereof, wherein said peptide has an antimicrobial activity.Type: GrantFiled: May 15, 2007Date of Patent: July 24, 2012Assignee: Dermagen ABInventors: Artur Schmidtchen, Martin Malmsten
-
Publication number: 20120184482Abstract: The invention relates to a ubiquitin-isopeptide probe (hereinafter also referred to as UIPP), a method for its preparation, and its use. The invention also provides a method for isolating a deubiquitinating enzyme and a method for activity-based protein profiling (ABPP).Type: ApplicationFiled: August 19, 2011Publication date: July 19, 2012Applicant: Helmholtz-Zentrum fuer Infektionsforschung GmbHInventors: Alexander Iphoefer, Raimo Franke, Antje Ritter, Tatjana Arnold, Lothar Jaensch
-
Publication number: 20120184498Abstract: The invention relates to the use of peptides corresponding to dermaseptin B2 or fragments thereof for treating proliferative diseases such as cancer or ocular lesions, and to pharmaceutical compositions containing such peptides.Type: ApplicationFiled: June 29, 2010Publication date: July 19, 2012Applicants: UNIVERSITÉ PARIS EST CRETEIL VAL DE MARNE, UNIVERSITÉ PIERRE ET MARIE CURIE (PARIS 6)Inventors: Jean Delbe, Mohamed Amiche, Ali Ladram, Cécile Galanth, Pierre Nicolas, Yamina Hamma, Johanna Allegonda Anna Van Zoggel, José Courty
-
Publication number: 20120183553Abstract: Disclosed are composition and methods for treating immune disorders. Also disclosed are diagnosis methods and prognosis methods.Type: ApplicationFiled: July 15, 2010Publication date: July 19, 2012Inventors: Zhenglun Zhu, Hong Gao
-
Publication number: 20120178676Abstract: The present invention relates to modified forms of C-peptide, and methods for their use. In one aspect, the modified forms of C-peptide comprise PEGylated C-peptide derivatives comprising at least one PEG group attached to the N-terminus, which exhibit superior pharmacokinetic and biological activity in vivo.Type: ApplicationFiled: May 17, 2011Publication date: July 12, 2012Applicant: CEBIX, INC.Inventors: Sheri Barrack, James Callaway, Michelle Mazzoni
-
Patent number: 8217001Abstract: Methods are disclosed for decreasing calorie intake, food intake, and appetite in a subject. The methods include peripherally administering a therapeutically effective amount of PYY or an agonist thereof to the subject, thereby decreasing the calorie intake of the subject.Type: GrantFiled: August 29, 2008Date of Patent: July 10, 2012Inventors: Michael Cowley, Roger Cone, Malcolm Low, Andrew Butler, Stephen Robert Bloom, Caroline Jane Small, Rachel Louise Batterham, Mohammad Ali Ghatei
-
Patent number: 8217139Abstract: The present invention provides peptides and pharmaceutical compositions thereof for appetite suppression and weight control. Preferred peptides are calcitonin analogs, preferably with specific amino acid changes to make the peptide more amylin-like.Type: GrantFiled: November 14, 2011Date of Patent: July 10, 2012Assignee: Unigene Laboratories, Inc.Inventors: Nozer M. Mehta, Amy Sturmer, William Stern, James P. Gilligan
-
Publication number: 20120172305Abstract: This invention provides methods of treatment using retro-inverso peptides derived from interleukin-6 (IL-6) having between 15 and about 40 amino acids, and including the sequence that is retro-inverso with respect to SEQ ID NO 1, i.e. wherein said peptide comprises the sequence D-Glu-D-Ala-D-Met-D-Lys-D-Pro-D-Leu-D-Asn-D-Leu-D-Asn-D-Asn-D-Glu-D-Ala-D-Leu-D-Ala-D-Glu. The peptides of the invention have the same activity as native IL-6 and also have neurotrophic activity. The peptides of the invention are also less susceptible to proteolytic degradation in vivo because of their D-amino acid linkage.Type: ApplicationFiled: October 28, 2011Publication date: July 5, 2012Applicant: MYELOS CORPORATIONInventors: DAVID E. WRIGHT, D. ELLIOT PARKS
-
Publication number: 20120172285Abstract: A series of stapled BCL-2 family peptide helices were identified as able to target the survival protein MCL-I with high affinity and a subset with unprecedented selectivity. Agents and methods for selective pharmacologic neutralization of MCL-I are provided for drug discovery and therapeutic uses, including use in overcoming the apoptotic resistance of cancer and other diseases associated with impaired cell death.Type: ApplicationFiled: December 9, 2009Publication date: July 5, 2012Inventors: Loren D. Walensky, Michelle L. Stewart
-
Publication number: 20120165262Abstract: The present invention provides therapeutic and prophylactic compositions for use in treating and preventing disorders involved epithelial cell apoptosis, such as gastrointestinal disorders (e.g., inflammatory bowel disease, Crohn's disease or ulcerative colitis) in a subject, such as a human patient.Type: ApplicationFiled: April 28, 2010Publication date: June 28, 2012Inventors: D. Brent Polk, Fang Yan
-
Publication number: 20120164123Abstract: Disclosed herein are methods of treating a subject with pulmonary disease including administering to the subject a therapeutically effective amount of a polypeptide including at least one arginine residue susceptible to ADP-ribosylation and nicotinamide adenine dinucleotide (NAD). In some embodiments, the polypeptide and/or NAD is administered via inhalation. Also disclosed is a pharmaceutical composition including at least one polypeptide (such as HNP-1) and NAD. The disclosure also provides in vitro methods of producing a polypeptide with altered activity, including contacting the polypeptide with NAD and an arginine-specific mono-ADP-ribosyltransferase (for example, ART1) to produce a polypeptide including at least one ADP-ribosylated arginine residue, incubating the ADP-ribosylated polypeptide under conditions sufficient for conversion of at least one ADP-ribosylated arginine residue to ornithine, and isolating the ornithine-containing polypeptide.Type: ApplicationFiled: September 8, 2010Publication date: June 28, 2012Inventors: Joel Moss, Linda Stevens, Rodney L. Levine
-
Publication number: 20120164127Abstract: This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.Type: ApplicationFiled: March 9, 2010Publication date: June 28, 2012Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey, Gregory Frost
-
Patent number: 8206693Abstract: Peptides are provided that have binding affinity for polymethyl methacrylate (PMMA). The polymethyl methacrylate-binding peptides may be used to prepare peptide-based reagents suitable for use in a variety of applications. The peptide-based reagents may be used to couple benefit agents to a PMMA polymer surface or may be used to couple a benefit agent comprising a PMMA polymer surface to a target surface, such as a body surface.Type: GrantFiled: May 12, 2010Date of Patent: June 26, 2012Assignee: E I du Pont de Nemours and CompanyInventors: Eberhard Schneider, Gregor Schurmann, Peter Wagner, Hong Wang
-
Patent number: 8207133Abstract: The present invention relates to the use of a regulatory protein RS1 fragment or a nucleic acid molecule encoding said regulatory protein RS1 fragment for the preparation of a pharmaceutical composition for the amelioration, prevention and/or treatment of a metabolic disease or a secondary disorder caused by a (pathological) modification of homeostasis, wherein said RS1 fragment is characterized in comprising at least 3 consecutive amino acid residues as comprised in the amino acid sequence S-D-S-D-R-I-E-P (Serine-Aspartic acid-Serine-Aspartic acid-Arginine-Isoleucine-Glutamic acid-Proline) (SEQ ID NO: 9) or derivatives thereof.Type: GrantFiled: March 31, 2006Date of Patent: June 26, 2012Assignee: Julius-Maximilians-Universitat WurzburgInventors: Herman Koepsell, Alexandra Vernaleken
-
Patent number: 8207128Abstract: Described is a polypeptide inhibiting the transmigration of leukocytes or the growth and/or metastasis of cancer cells, a fusion protein thereof, a polynucleotide encoding the polypeptide, a vector including the polynucleotide, and a transformant transformed with the vector. Described is also a pharmaceutical composition for the prevention or treatment of inflammatory diseases, or the inhibition of the growth and/or metastasis of cancer cells including the polypeptide or a fusion protein thereof.Type: GrantFiled: September 20, 2006Date of Patent: June 26, 2012Assignee: Supadelixir Inc.Inventors: Jang-Hee Hahn, Kyoung-Jin Lee, Dong-Min Kang
-
Publication number: 20120157372Abstract: The present invention provides for novel peptides derived from human milk In aspects of the invention, the peptides are capable, individually or in combination, of evoking an antioxidative stress response, immunomodulation, anti-inflammatory response and anti-pathogenic response. As such the peptides of the invention may be used in food supplements, milk substitutions, infant formula., mother's milk, parenteral nutrition solutions, cell/tissue/organ storage and perfusion solutions and pharmaceutical formulations.Type: ApplicationFiled: June 1, 2010Publication date: June 21, 2012Inventors: Kenneth James Friel, Apollinaire Tsopmo
-
Publication number: 20120156134Abstract: Disclosed are agents (e.g., peptides, polypeptides, proteins, small molecules, antibodies, and antibody fragments that target senescent cells) and methods of their use for imaging senescent cells in vivo and for treating or preventing cancer, age-related disease, tobacco-related disease, or other diseases and disorders related to or caused by cellular senescence in a mammal. The methods include administering one or more of the agents of the invention to a mammal, e.g., a human. The agents, which specifically bind to senescent cells, can be labeled with a radioactive label or a therapeutic label, e.g., a cytotoxic agent.Type: ApplicationFiled: December 19, 2008Publication date: June 21, 2012Inventor: Shayne Squires
-
Publication number: 20120157379Abstract: Novel gastric inhibitory peptide (GIP) polypeptide compositions are provided. Human GIP alleles encode an extended peptide, referred to herein as GIP55S or GIP55G, which is resistant to serum degradation, relative to the known mature GIP peptide. GIP55S or GIP55G peptides find use where it is desirable to modulate insulin secretion.Type: ApplicationFiled: July 29, 2010Publication date: June 21, 2012Inventor: Sheau Yu Hsu
-
Patent number: 8202841Abstract: Some embodiments relate to analogs of peptides corresponding to class I MHC-restricted T cell epitopes and methods for their generation. These analogs can contain amino acid substitutions at residues that directly interact with MHC molecules, and can confer improved, modified or useful immunologic properties. Additionally classes of analogs, in which the various substitutions comprise the non-standard residues norleucine and/or norvaline, are disclosed.Type: GrantFiled: June 17, 2005Date of Patent: June 19, 2012Assignee: MannKind CorporationInventors: Liping Liu, Zhidong Xie, David C. Diamond
-
Patent number: 8202835Abstract: The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.Type: GrantFiled: July 15, 2008Date of Patent: June 19, 2012Inventor: Yitzchak Hillman
-
Publication number: 20120149635Abstract: The present invention provides peptides and pharmaceutical compositions thereof for appetite suppression and weight control. Preferred peptides are calcitonin analogs, preferably with specific amino acid changes to make the peptide more amylin-like.Type: ApplicationFiled: November 14, 2011Publication date: June 14, 2012Applicant: Unigene Laboratories Inc.Inventors: Nozer M. Mehta, Amy Sturmer, William Stern, James P. Gilligan
-
Publication number: 20120148590Abstract: The invention provides cell-permeable peptides that bind to JNK protein and inhibit JNK-mediated effects in JNK-expressing cells.Type: ApplicationFiled: September 25, 2011Publication date: June 14, 2012Inventor: Christophe Bonny
-
Publication number: 20120148642Abstract: Disclosed herein are peptides or peptide analogs with multiple amphipathic ?-helical domains that promote lipid efflux from cells via an ABCA1-dependent pathway. Also provided herein are methods of using multi-domain amphipathic ?-helical peptides or peptide analogs to treat or inhibit dyslipidemic disorders. Methods for identifying non-cytotoxic peptides that promote ABCA1-dependent lipid efflux from cells are also disclosed herein.Type: ApplicationFiled: February 28, 2012Publication date: June 14, 2012Applicants: Health and Human ServicesInventors: Alan T. Remaley, Stephen J. Demosky, John A. Stonik, Marcelo J.A. Amar, Edward B. Neufeld, H. Bryan Brewer, Fairwell Thomas
-
Publication number: 20120149651Abstract: The present invention relates generally to compositions and methods useful for treating various conditions and afflictions, such as inflammation and cancer. More specifically, the present invention relates to compositions and methods of treatment which utilize peptides comprising at least one caveolin scaffolding domain. Even more specifically, the present invention relates to compositions of fusion peptides comprising the antennapedia homeodomain fused to a caveolin scaffolding domain and to methods of using these peptides to treat various conditions and afflictions.Type: ApplicationFiled: October 30, 2007Publication date: June 14, 2012Applicant: Yale UniversityInventor: William C. Sessa
-
Publication number: 20120149649Abstract: The present invention provides a cationic polyamino acid suitable for a carrier that can form a stable complex with a nucleic acid under a physiological condition and release the nucleic acid in cells suitably. The cationic polyamino acid can associate with a nucleic acid and includes a cationic amino acid residue having a cationic group in a side chain and a hydrophobic amino acid residue having a hydrophobic group in a side chain. The cationic polyamino acid includes 1 to 20 units of the cationic amino acid residue and is represented by the following formula (1). The meaning of each symbol in the formula is as shown in the description.Type: ApplicationFiled: February 23, 2011Publication date: June 14, 2012Applicants: THE UNIVERSITY OF TOKYO, NANOCARRIER CO., LTD.Inventors: Yasuki Kato, Atsushi Ishii, Naoya Shibata, Tatsuyuki Hayashi, Kazunori Kataoka, Kanjiro Miyata, Nobuhiro Nishiyama
-
Patent number: 8198242Abstract: The present disclosure provides variants of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising CNP variants, and methods of making CNP variants. The CNP variants are useful as therapeutic agents for the treatment of diseases responsive to CNP, including but not limited to bone-related disorders, such as skeletal dysplasias (e.g., achondroplasia), and vascular smooth muscle disorders (e.g., restenosis and arteriosclerosis).Type: GrantFiled: May 20, 2010Date of Patent: June 12, 2012Assignee: Biomarin Pharmaceutical Inc.Inventors: Daniel J. Wendt, Shinong Long, Sianna Castillo, Christopher P. Price, Mika Aoyagi-Scharber, Michel C. Vellard, Augustus O. Okhamafe
-
Publication number: 20120141416Abstract: The present invention relates to multimeric (e.g., dimeric, trimeric) forms of peptide vectors that are capable of crossing the blood-brain barrier (BBB) or efficiently entering particular cell types. These multimeric peptide vectors, when conjugated to agents (e.g., therapeutic agents) are capable of transporting the agents across the BBB or into particular cell types. These compounds are therefore particularly useful in the treatment of neurological diseases.Type: ApplicationFiled: June 30, 2010Publication date: June 7, 2012Applicant: Angiochem Inc.Inventors: Michel Demeule, Christian Che, Carine Thiot
-
Publication number: 20120142611Abstract: A repeat protein from a collection of repeat proteins, wherein each repeat protein of said collection comprises a repeat domain, which comprises a set of consecutive repeat modules, wherein the repeat modules have the same fold and stack tightly to create a superhelical structure having a joint hydrophobic core, wherein each of the repeat modules is derived from one or more repeat units and wherein the repeat units comprise framework residues, which contribute to the folding topology of the repeat unit or contribute to an interaction with a neighboring repeat unit, and target interaction residues, which contribute to an interaction with a target substance, wherein the repeat proteins of the collection differ from other repeat proteins in the collection in at least one amino acid position of the repeat modules is described as are related pharmaceuticals and nucleic acid molecules.Type: ApplicationFiled: December 19, 2011Publication date: June 7, 2012Applicant: UNIVERSITAT ZURICHInventors: Michael Tobias STUMPP, Patrik Forrer, Hans Kaspar Binz, Andreas Pluckthun
-
Publication number: 20120142613Abstract: The invention provides cell-permeable peptides that bind to JNK proteins and inhibit JNK-mediated effects in JNK-expressed cells.Type: ApplicationFiled: August 31, 2011Publication date: June 7, 2012Inventor: Christophe Bonny
-
Patent number: 8193153Abstract: This invention relates to methods and compositions for detection and treatment of retinal degenerative diseases. In particular, the invention relates to polypeptides that can protect against cone degeneration, nucleic acid molecules that encode such polypeptides, and antibodies that recognize said polypeptides.Type: GrantFiled: December 5, 2008Date of Patent: June 5, 2012Assignee: INSERM (Institut National de la Sante et de la Recherche Medicale)Inventors: Thierry Leveillard, Jose-Alain Sahel, Valerie Fontaine
-
Publication number: 20120135916Abstract: Methods are disclosed for determining progression of a condition, onset of a condition, or efficacy of treatment of a condition characterized by an adipocyte imbalance in a patient. In addition, methods are disclosed of treating diabetes, abnormal adipocyte activity, and insulin resistance using monomeric, homodimeric, and heterodimeric forms of certain C-terminal fragments of adiponectin receptor. In addition, methods of treating abnormal adipocyte activity, treating metabolic syndrome, causing insulin secretion, increasing insulin levels, inhibiting insulin degradation enzyme, treating Alzheimer's disease, treating cardiovascular disease associated with adiponectin levels, inhibiting ADAM-17 enzyme, inhibiting a protease, treating a condition associated with TNF-alpha, and treating a condition associated with HER2-neu are disclosed. Compositions, dosage forms, and kits are also disclosed.Type: ApplicationFiled: April 13, 2010Publication date: May 31, 2012Applicant: Siemens Healthcare Diagnostics Inc.Inventors: Michael J. Pugia, Rui Ma
-
Patent number: 8188046Abstract: The application describes several mutant amyloid beta peptides and specific regions which are useful in the therapeutic and diagnostic of neurological diseases. The application further describes methods of using these mutant peptides as treatment and reagents for diagnosis of diseases. The application further describes diagnostic kits and pharmaceutical compositions for use in therapy to treat neurological diseases including but not limited to Alzheimer's disease and various forms of mild cognitive impairments.Type: GrantFiled: October 12, 2007Date of Patent: May 29, 2012Assignee: University of South FloridaInventor: Chuanhai Cao
-
Patent number: 8188222Abstract: [Problems] A derivative of a nucleic acid antimetabolite is demanded which can show a higher therapeutic effect at a lower dose. [Means for Solving Problems] Disclosed is a high molecular weight derivative a nucleic acid antimetabolite, which is characterized by comprising a high molecular weight compound comprising a polyethylene glycol moiety and a polymer moiety having a carboxyl group in a side chain and a nucleoside derivative which can act as a nucleic acid antimetabolite, wherein the nucleoside derivative is bound to the carboxyl group in the side chain of the high molecular weight compound via a highly hydrophobic linker.Type: GrantFiled: November 6, 2007Date of Patent: May 29, 2012Assignee: Nippon Kayaku Kabushiki KaishaInventors: Keiichiro Yamamoto, Kazutoshi Takashio
-
Patent number: 8187587Abstract: The present invention discloses the protease stratum corneum chymotrytic enzyme (SCCE) is specifically over-expressed in ovarian and other malignancies. A number of SCCE peptides can induce immune responses to SCCE, thereby demonstrating the potential of these peptides in monitoring and the development of immunotherapies for ovarian and other malignancies.Type: GrantFiled: December 26, 2007Date of Patent: May 29, 2012Assignee: Board of Trustees of the University of ArkansasInventors: Timothy J. O'Brien, Martin J. Cannon, Alessandro Santin, Kristina L. Bondurant
-
Publication number: 20120129776Abstract: Disclosed are peptide ligands for G-protein coupled receptors that are useful for treating disorders associated with G-protein coupled receptor activation.Type: ApplicationFiled: September 18, 2007Publication date: May 24, 2012Inventors: Yossi Cohen, Ronen Shemesh, Amir Toporik, Zurit Levine, Assaf Wool, Dvir Dahary, Iris Hecht, Merav Beiman, Galit Rotman, Michal Ayalon-Soffer
-
Patent number: 8183201Abstract: The invention provides disintegrin variants, and more specifically to disintegrin variants which are selective ?v?3 integrin antagonists for treatment and prevention of ?v?3 integrin-associated diseases. The present invention also relates to pegylated proteins, including proteins comprising a disintegrin variant having an RGD motif variant 48ARLDDL53. The invention also relates to the use of the polypeptides of the invention for the treatment and prevention of ?v?3 integrin-associated diseases.Type: GrantFiled: February 25, 2011Date of Patent: May 22, 2012Assignees: National Cheng Kung University, National Taiwan UniversityInventors: Woei-Jer Chuang, Wen-Mei Fu, Mannching Sherry Ku, Yen-Lun Huang
-
Patent number: 8183210Abstract: Reconstituted surfactants comprising a lipid carrier, a polypeptide analog of the native surfactant protein SP-C, and a polypeptide analog of the native surfactant protein SP-B are useful for the treatment and/or prophylaxis of RDS and other respiratory disorders.Type: GrantFiled: April 13, 2009Date of Patent: May 22, 2012Assignee: Chiesi Farmaceutici S.p.A.Inventors: Jan Johansson, Tore Curstedt, Bengt Robertson, Joakim Robertson, legal representative, Soeren Robertson, legal representative, Magnus Robertson, legal representative, Charlotte Robertson, legal representative, Gertie Robertson Grossmann, legal representative
-
Publication number: 20120121590Abstract: The invention provides Galectin-3 binding protein (Gal-3BP, BTBD17B) polypeptide sequences and compositions that include Gal-3BP polypeptide sequences, and methods of using Gal-3BP polypeptide sequences, including modified forms and wild type (native) forms of Gal-3BP polypeptide, such as in treatment, diagnostic, detection and prognostic methods.Type: ApplicationFiled: April 16, 2010Publication date: May 17, 2012Inventors: Klaus Ley, Christian Gleissner